Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway

Tumor Biology

Volumn 36, Issue 5, 2015, Pages 3591-3599

  Chen, Ping ^a   Li, Jian ^a   Jiang, He Guo ^a   Lan, Ting ^b   Chen, Yong Chang ^b  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

Author keywords

Cisplatin; Curcumin; DNA repair; FA BRCA pathway; Lung cancer cells; Resistance

Indexed keywords

CISPLATIN; CURCUMIN; FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA PROTEIN; FANCD2 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL PROLIFERATION; CHROMATIN CONDENSATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DNA FRAGMENTATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC50; LUNG CANCER; PRIORITY JOURNAL; UBIQUITINATION; WESTERN BLOTTING; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; DNA REPAIR; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CURCUMIN; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84929958724     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2996-4     Document Type: Article

References (38)

1. Spira SG, Silvestri GA. The treatment of advanced non-small cell lung cancer. Curr Opin Pulm Med. 2005;11:287–91.
2. Massarelli E, Herbst RS. Use of novel second-line target therapies in non-small cell lung cancer. Semin Oncol. 2006;33 suppl 1:s9–16.
3. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379–92.
4. Resell R, Cecere F, Santarpia M, Noemi R, Miquel T. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol. 2006;6:323–31.
5. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001;478:23–43.
6. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573–84.
7. Kennedy RD, D’Andrea AD. DNA repair pathway in clinical practice: lesions from pediatric cancer susceptibility syndromes. J Clin Oncol. 2006;24:3799–808.
8. Kim H, D’Andrea AD. Regulation of DNA Cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev. 2012;26:1393–408.
9. Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res. 2009;668:4–10.
10. Alan D. The Fanconi anemia and breast susceptibility pathway. N Engl J Med. 2010;362:1909–19.
11. Kee Y, D’Andrea AD. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev. 2010;24:1680–94.
12. Su X, Huang J. The Fanconi anemia pathway and DNA interstrand cross-link repair. Protein Cell. 2011;2:704–11.
13. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 2003;9:568–74.
14. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA-mutated cancers. Nature. 2008;451:1116–20.
15. Jagtap S, Meganathan K, Wagh V, Winkler J, Hescheler J, Sachinidis A. Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and cardiovascular diseases. Curr Med Chem. 2009;16:1451–62.
16. Shishodia S, Chalurvedi MM, Aggarwal BB. Role of curcumin in cancer therapy. Curr Probl Cancer. 2007;31:243–305.
17. Ye MX, Li Y, Yin H, Zhang J. Curcumin: updated molecular mechanisms and intervention targets in human lung cancer. Int J Mol Sci. 2012;13:3959–78.
18. Duarte VM, Han E, Veena MS, Salvado A, Suh JD, Liang LJ, et al. Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKβ protein of the NFκB pathway. Mol Cancer Ther. 2010;9:2665–75.
19. Xu XB, Chen B, Liu WY. Curcumin inhibits the invasion of thyroid cancer cells via down-regulation of PI3K/kt signaling pathway. Gene. 2014;546:226–32.
20. Zang S, Liu T, Shi J, Qiao L. Curcumin: a promising agent targeting cancer stem cells. Anticancer Agents Med Chem. 2014;14:787–92.
21. Chirnomas D, Taniguchi T, de la Vaga M, Vaidya AP, Vasserman M, Hartman A-R, et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther. 2006;5:952–61.
22. Xiao H, Xiao Q, Zhang K, Zuo X, Shresthan UK. Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R. Ann Hematol. 2010;89:399–404.
23. Shao Z-M, Shen Z-Z, Liu C-H, Sartippour MR, Heber D, Nguyen M. Curcumin exerts multiples suppressive effects on human breast carcinoma cells. Int J Cancer. 2002;98:234–40.
24. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood. 2005;106:698–705.
25. van der Heijden MS, Brody JR, Gallemier E, Cunningham SC, Dezentje DA, Shen D, et al. Function defects in the Fanconi anemia pathway in pancreatic cancer cells. Am J Pathol. 2004;165:651–7.
26. Burkitt K, Ljungman M. Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines. Cancer Lett. 2007;8:131–7.
27. Zhang J, Wang X, Lin C-J, Conch FJ, Fei P. Altered expression of FANCL confers mitomycin C sensitivity in calu-6 lung cancer cells. Cancer Biol Ther. 2006;5:1632–6.
28. Burkitt K, Ljurgman M. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitized head and neck cancer cells to cisplatin. Mol Cancer. 2008;7:24.
29. Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, et al. Targeting the Fanconi anemial BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res. 2009;69:9367–75.
30. Chen J, Dexheimer TS, Ai Y, Liang G, Villamil MA, Inglese J, et al. Selective and cell-active inhibitors of the USP1/UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem Biol. 2011;18:1390–400.
31. Kee Y, Huang M, Chang S, Moreau LA, Park E, Smith PG, et al. Inhibition of the Nedd8 system sensitive cells to DNA interstrand cross-linking agents. Mol Cancer Res. 2012;10:369–77.
32. Litan R, Gupta R, Brosh Jr RM, Cantor SB. BRCA-FA pathway as a target for anti-tumor drugs. Anticancer Agents Med Chem. 2008;8:423–30.
33. Hucl T, Gallmeier E. DNA repair: exploiting the Fanconi anemia pathway as a potential therapeutic target. Physiol Res. 2011;60:453–65.
34. Shukl P, Solank A, Ghos K, Vundinit BR. DNA interstrand cross-link repair: understanding role of Fanconi anemia pathway and therapeutic implications. Eur J Haematol. 2013;9:381–93.
35. Kunnunakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling protein. Cancer Lett. 2008;269:199–255.
36. Yu LL, Wu JG, Dai HG, Si JM. Curcumin reverses chemoresistance of human gastric cancer cells by downregulating the NF-Kappa B transcritption factor. Oncol Rep. 2011;26:1197–203.
37. Jana NR, Diskshit P, Goswami A, Nukina N. Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem. 2004;219:11680–5.
38. Jacquemont C, Taniguchi T. Proteasome function is required for DNA damage response and Fanconi anemia pathway activation. Cancer Res. 2007;67:7395–405.